Sign in
Taking peoplePhase 3

A Study to Evaluate a New Treatment Option for Helicobacter pylori Infection Compared to First Line Treatment.

Key facts

Who runs it
Verisfield Single Member S.A.
Where
Greece17 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
420 people, planned
Started
7 Jul 2026
Expected to end
30 Jun 2027
Type of study
Interventional
Record updated
28 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age ≥18 years
  • Diagnosed active H. pylori infection established by gastroscopy and CLO test
  • No prior treatment for H. pylori infection
  • Clear indication for eradication therapy
  • Willingness and ability to receive the study medication in the specified dose and frequency throughout the study duration
  • Willingness to provide voluntary written informed consent before any clinical trial related procedure is performed (also refers to legally authorized representatives, where applicable)

Who cannot take part

  • Use of any of the following concomitant medications during participation in the study and within timeframes shorter than the required washout periods: a. Antibiotics: Within the previous 4 weeks. b. PPIs or PCABs: Within the previous 2 weeks. c. Bismuth Compounds: Within the previous 4 weeks
  • History of substance or alcohol abuse within 1 year prior to the study
  • Use of any of the following prohibited medications during participation in the study and within timeframes shorter than the required washout periods: a) Chronic or regular use of non-steroidal anti-inflammatory drugs (NSAIDs) and/or systemic glucocorticoids (steroids) within the past 4 weeks. b) Use of anticoagulants (e.g., warfarin, DOACs) or antiplatelet agents within the past 4 weeks, with the exception of low-dose aspirin (≤100 mg/day)
  • Use of any prohibited concomitant medication with known clinically significant or serious interactions with the study treatments, as defined in this protocol (Section 9.1), in the opinion of the Investigator
  • Prior gastric surgery/gastrectomy or other upper gastrointestinal surgery
  • Zollinger-Ellison syndrome
  • Significant organ dysfunction; severe or unstable cardiopulmonary or endocrine disease
  • Gastrointestinal bleeding or related iron-deficiency anemia (IDA); Barrett’s esophagus or high-grade dysplasia; dysphagia; idiopathic thrombocytopenic purpurea (ITP)
  • Cockayne Syndrome
  • Hypersensitivity to any of the active substances (metronidazole, bismuth, tetracycline, amoxicillin, clarithromycin, esomeprazole, 13C-urea), to any of the excipients, to other penicillins, macrolide antibiotics, nitroimidazole derivatives, or substituted benzimidazoles. History of a severe immediate hypersensitivity reaction (e.g., anaphylaxis) to another beta-lactam agent (e.g., a cephalosporin, carbapenem, or monobactam)
  • Severe comorbidity (e.g., advanced renal, hepatic, or cardiac failure) or malignancy
  • Patients with hypokalaemia or hypomagnesaemia, due to the risk of prolongation of the QT interval
  • Any medical condition or laboratory abnormality during theScreening Period that, in the opinion of the Investigator, is clinically significant and could interfere with the participant's abilityto be included in the study
  • History of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes
  • Documented or suspected atrophic gastritis, which might interfere with the urea breath test (contraindication for Helicobacter Test INFAI)
  • Pregnancy or lactation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of the study is to demonstrate the non-inferiority of the fixed combination Test product compared to the standard first-line therapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.
Record updated
28 August 2026